Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
Nautilus Biotechnology (NAUT) will report third-quarter 2026 financial results before market open on October 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology (NAUT) will report third-quarter 2026 financial results before market open on October 27, 2026.
Management will host a webcast conference call at 5:30 a.m. Pacific / 8:30 a.m. Eastern to discuss results, business developments and outlook. Live audio will be available in the Investors section at www.nautilus.bio.
Details
Market move: NAUT -4.86% vs previous close. 3Q26 earnings report
On Oct 15, the day this news came out, the latest delayed price for NAUT is 4.86% below the previous close. Argus tracked a trough of -9.2% from its starting point during tracking. Our momentum scanner has recorded 25 alerts for this stock so far that day. The latest delayed price is $2.06.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
